Chao Wang ¹ Yunzhuo Dong ^1* Peng Men ^2* Ruixia Zhang ^1* Ying Xiao ^1* Yishan Bu ^1* Yinpeng Qin ^1* Xinran Zhang ^1* Qianqian Dou ^1* Yiheng Yang ^2* Huier Gao ^1* Yi Zhang ^1*

• ¹ Tianjin First Central Hospital, Tianjin, China
• ² Peking University Third Hospital, Haidian, Beijing Municipality, China

Obinutuzumab was approved in China in June 2021 used in combination with chemotherapy (followed by obinutuzumab maintenance) for the treatment of adult patients with previously untreated stage II bulky, III, or IV follicular lymphoma (FL). The clinical application of obinutuzumab has recently begun in China, but there is a lack of evidence to determine under which circumstances it should be considered the treatment of choice.We conducted a rapid review to summarized the efficacy, safety, and cost-effectiveness of obinutuzumab in adult patients with FL. The approach to the rapid review was that evidence synthesis of systematic reviews/meta-analyses, health technology assessment (HTA) reports, and pharmacoeconomic studies. Its purpose is to provide healthcare professionals with scientific information and evidence for rational treatment choices. In our study, we found that obinutuzumab plus chemotherapy significantly prolonged progression free survival (PFS) compared to other chemotherapies at primary and updated analyses. The incidence of grade 3-5 adverse events(AEs), infusion-related reactions (IRRs), and infection were higher in the obinutuzumab based chemotherapy compared to other chemotherapies group. The economic researches conducted in China, United States, Japan, Italy and Norway had demonstrated that obinutuzumab-based chemothrepy was cost-effective compared to other chemothrepies . Although obinutuzumab significantly prolonged PFS and is cost-effective, its safety profile is considered lower. Therefore, medical professionals should be caution when using or introducing obinutuzumab treatment for FL patients.